News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
737,468 Results
Type
Article (43058)
Company Profile (282)
Press Release (694115)
Multimedia
Podcasts (85)
Webinars (17)
Section
Business (208563)
Career Advice (2056)
Deals (36007)
Drug Delivery (113)
Drug Development (82915)
Employer Resources (174)
FDA (16614)
Job Trends (15186)
News (352756)
Policy (33325)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2672)
Accelerated approval (31)
Adcomms (25)
Allergies (140)
Alliances (50695)
ALS (173)
Alzheimer's disease (1695)
Antibody-drug conjugate (ADC) (310)
Approvals (16881)
Artificial intelligence (542)
Autoimmune disease (146)
Automation (38)
Bankruptcy (366)
Best Places to Work (11811)
BIOSECURE Act (20)
Biosimilars (192)
Biotechnology (185)
Bladder cancer (158)
Brain cancer (58)
Breast cancer (640)
Cancer (4839)
Cardiovascular disease (407)
Career advice (1739)
Career pathing (36)
CAR-T (280)
CDC (44)
Celiac Disease (2)
Cell therapy (746)
Cervical cancer (36)
Clinical research (70538)
Collaboration (1733)
Company closure (4)
Compensation (1166)
Complete response letters (52)
COVID-19 (2758)
CRISPR (91)
C-suite (845)
Cystic fibrosis (148)
Data (6242)
Decentralized trials (2)
Denatured (28)
Depression (133)
Diabetes (498)
Diagnostics (6773)
Digital health (45)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (258)
Drug pricing (188)
Drug shortages (28)
Duchenne muscular dystrophy (226)
Earnings (91542)
Editorial (56)
Employer branding (21)
Employer resources (152)
Events (120299)
Executive appointments (1005)
FDA (19733)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1495)
Gene editing (198)
Generative AI (47)
Gene therapy (601)
GLP-1 (973)
Government (4737)
Grass and pollen (7)
Guidances (385)
Healthcare (19328)
HIV (57)
Huntington's disease (45)
IgA nephropathy (81)
Immunology and inflammation (252)
Immuno-oncology (55)
Indications (103)
Infectious disease (3023)
Inflammatory bowel disease (189)
Inflation Reduction Act (14)
Influenza (115)
Intellectual property (246)
Interviews (320)
IPO (16786)
IRA (50)
Job creations (3718)
Job search strategy (1456)
JPM (56)
Kidney cancer (15)
Labor market (83)
Layoffs (557)
Leadership (30)
Legal (8098)
Liver cancer (93)
Longevity (15)
Lung cancer (647)
Lymphoma (374)
Machine learning (44)
Management (59)
Manufacturing (796)
MASH (166)
Medical device (13889)
Medtech (13942)
Mergers & acquisitions (20285)
Metabolic disorders (1267)
Multiple sclerosis (158)
NASH (16)
Neurodegenerative disease (316)
Neuropsychiatric disorders (86)
Neuroscience (2926)
Neurotech (1)
NextGen: Class of 2026 (6668)
Non-profit (4629)
Now hiring (65)
Obesity (591)
Opinion (262)
Ovarian cancer (165)
Pain (198)
Pancreatic cancer (225)
Parkinson's disease (287)
Partnered (33)
Patents (489)
Patient recruitment (481)
Peanut (57)
People (59947)
Pharmaceutical (63)
Pharmacy benefit managers (29)
Phase 1 (22044)
Phase 2 (30981)
Phase 3 (23087)
Pipeline (5129)
Policy (281)
Postmarket research (2651)
Preclinical (9628)
Press Release (68)
Prostate cancer (242)
Psychedelics (47)
Radiopharmaceuticals (283)
Rare diseases (838)
Real estate (6099)
Recruiting (69)
Regulatory (24837)
Reports (51)
Research institute (2504)
Resumes & cover letters (356)
Rett syndrome (27)
RNA editing (16)
RSV (76)
Schizophrenia (148)
Series A (249)
Series B (187)
Service/supplier (13)
Sickle cell disease (100)
Special edition (21)
Spinal muscular atrophy (164)
Sponsored (44)
Startups (3692)
State (2)
Stomach cancer (17)
Supply chain (106)
Tariffs (84)
The Weekly (55)
Vaccines (995)
Venture capital (89)
Weight loss (378)
Women's health (88)
Worklife (18)
Date
Last 7 days (607)
Last 30 days (1994)
Last 365 days (30518)
2026 (2889)
2025 (30987)
2024 (35786)
2023 (40531)
2022 (51743)
2021 (56314)
2020 (54805)
2019 (47489)
2018 (35754)
2017 (32675)
2016 (32260)
2015 (38357)
2014 (32048)
2013 (27138)
2012 (29438)
2011 (30048)
2010 (28279)
Location
Africa (766)
Alabama (84)
Alaska (7)
Arizona (311)
Arkansas (13)
Asia (40059)
Australia (6543)
California (11328)
Canada (3276)
China (1108)
Colorado (479)
Connecticut (485)
Delaware (334)
Europe (87727)
Florida (1692)
Georgia (356)
Hawaii (3)
Idaho (61)
Illinois (872)
India (63)
Indiana (521)
Iowa (23)
Japan (422)
Kansas (125)
Kentucky (39)
Louisiana (26)
Maine (72)
Maryland (1391)
Massachusetts (8189)
Michigan (319)
Minnesota (634)
Mississippi (5)
Missouri (127)
Montana (33)
Nebraska (28)
Nevada (122)
New Hampshire (85)
New Jersey (3097)
New Mexico (30)
New York (3000)
North Carolina (1567)
North Dakota (10)
Northern California (5502)
Ohio (336)
Oklahoma (22)
Oregon (42)
Pennsylvania (2285)
Puerto Rico (22)
Rhode Island (47)
South America (1137)
South Carolina (65)
South Dakota (1)
Southern California (4415)
Tennessee (175)
Texas (1745)
United States (40478)
Utah (337)
Vermont (1)
Virginia (263)
Washington D.C. (83)
Washington State (925)
West Virginia (4)
Wisconsin (123)
Wyoming (2)
737,468 Results for "model n inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Ferring’s Shift to New Business Model Claims 500 Jobs Worldwide
The layoffs are part of the company’s shift to a new structure enabling cost efficiency for its new model.
October 9, 2025
·
2 min read
·
Tristan Manalac
Press Releases
1910 Publishes CANDID-CNS™, an AI Model That Unlocks Beyond Rule of 5 Chemical Space and Stereochemistry to Predict Blood–Brain Barrier Penetration
● CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. ● CANDID-CNS™ distinguishes CNS penetrant stereoisomers at 68% compared to 50% by Pfizer’s CNS MPO. ● Published in the Journal of Chemical Information and Modeling, CANDID-CNS™ presents a breakthrough in AI Drug Discovery by unlocking the potential of bRo5 and stereochemistry to significantly expand the chemical space of small molecules that can be developed into CNS therapeutics.
December 4, 2025
·
1 min read
Press Releases
Model Medicines Unveils Groundbreaking Preclinical Data: Oral MDL-001 Demonstrates Superiority or Equivalence to Three Standard-of-Care Antivirals: Nirmatrelvir, Remdesivir, and Sofosbuvir, Across Respiratory and Hepatic Viral Diseases
Oral MDL-001 Demonstrated Equivalence to Remdesivir and Sofosbuvir in Head-to-Head Animal Model Studies Performed at The Icahn School of Medicine at Mount Sinai and Scripps Research, and Superiority to Nirmatrelvir in a Literature Comparison of Equivalent Animal Models. The Potential First-in-Category, Direct-Acting, Broad-Spectrum Antiviral Targets A Novel Conserved Site on The Viral Polymerase Across Six Viral Families.
December 4, 2025
·
1 min read
Press Releases
Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models
January 9, 2026
·
3 min read
Press Releases
Organoid : Organ or Model? Navigating the Scientific Hype - Commentary by Unexakorea
January 26, 2026
·
1 min read
Press Releases
Battelle Awarded U.S. EPA STREAMS V Contract to Deliver Nationwide Scientific, Technical, Research, Engineering, and Modeling Support
February 6, 2026
·
2 min read
Press Releases
Model Medicines to Present 325 Billion Molecule Throughput Oncology Screen, at Google Cloud’s Cancer AI Symposium
At Google Cloud’s second annual Cancer AI Symposium, Model Medicines will unveil how its GALILEO™ platform, built on Google Cloud, powered a 325 billion molecule throughput oncology screen — the largest of its kind — opening the door to trillion‑scale discovery and culminating in the discovery of MDL‑4102, a potent and selective BRD4 inhibitor.
October 30, 2025
·
1 min read
Press Releases
Allelica Licenses University of Cambridge BOADICEA Model to Deliver Comprehensive Breast Cancer Risk Assessment
January 22, 2026
·
2 min read
Press Releases
BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development
January 6, 2026
·
2 min read
Press Releases
Animate Biosciences’ Engineered Peptides Match or Exceed Standard Therapy in Preclinical Lung Fibrosis Models
January 14, 2026
·
3 min read
1 of 73,747
Next